Cheryl Scott Sells 1,462 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott sold 1,462 shares of the stock in a transaction on Friday, June 28th. The shares were sold at an average price of $28.39, for a total value of $41,506.18. Following the completion of the sale, the director now owns 10,098 shares in the company, valued at $286,682.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Progyny Stock Down 0.2 %

NASDAQ PGNY opened at $28.33 on Wednesday. Progyny, Inc. has a 52-week low of $23.90 and a 52-week high of $44.95. The business’s 50-day moving average price is $28.44 and its 200 day moving average price is $34.09. The firm has a market cap of $2.70 billion, a P/E ratio of 46.44, a P/E/G ratio of 1.85 and a beta of 1.46.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The firm had revenue of $278.08 million for the quarter, compared to analyst estimates of $289.41 million. During the same quarter last year, the company posted $0.18 earnings per share. The business’s revenue was up 7.6% on a year-over-year basis. As a group, analysts anticipate that Progyny, Inc. will post 0.73 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on PGNY. Canaccord Genuity Group cut their price target on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Barclays cut their price target on Progyny from $48.00 to $30.00 and set an “overweight” rating on the stock in a research note on Monday, May 13th. BTIG Research cut their price target on Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $48.00 price target on shares of Progyny in a research note on Thursday, May 16th. Finally, Truist Financial dropped their price objective on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 17th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.11.

Institutional Investors Weigh In On Progyny

A number of hedge funds have recently added to or reduced their stakes in PGNY. Acadian Asset Management LLC acquired a new stake in Progyny in the third quarter valued at about $53,000. Federated Hermes Inc. lifted its position in Progyny by 16.5% in the third quarter. Federated Hermes Inc. now owns 26,648 shares of the company’s stock valued at $907,000 after purchasing an additional 3,771 shares during the period. Northern Trust Corp lifted its position in Progyny by 1.3% in the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock valued at $39,695,000 after purchasing an additional 15,208 shares during the period. PEAK6 Investments LLC acquired a new stake in Progyny in the third quarter valued at about $288,000. Finally, Qube Research & Technologies Ltd lifted its position in Progyny by 27.6% in the third quarter. Qube Research & Technologies Ltd now owns 135,518 shares of the company’s stock valued at $4,610,000 after purchasing an additional 29,273 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.